Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T20:46:10.503Z.
Consensus retrieved: 2026-10-06T10:36:06.782Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T20:46:10.503Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7d2b810459fcea1e9aa106a928442b73bf826bd09a5c75c69395a3c454dfad86
Forward PE Ratio (N/A) = Dated Quote Price ($2.56) / Consensus Forward EPS ($-0.38)
FORWARD PE RATIO
N/A
CytomX Therapeutics, Inc.
Market Cap
$557.32M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | $557.32M | N/A |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $548.51M | N/A |
| CorMedix Inc. (CRMD)vs › | $571.13M | 14.71 |
| ProKidney Corp. (PROK)vs › | $538.01M | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $578.40M | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | N/A |
| OrthoPediatrics Corp. (KIDS)vs › | $583.31M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.56, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.38 | $-0.41 – $-0.35 | 6 | n/m |
| 2027-12-31 | $-0.46 | $-0.59 – $-0.34 | 6 | n/m |
| 2028-12-31 | $-0.51 | $-0.76 – $-0.11 | 5 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
